AMRI signs agreement with an Australian firm Parnell

2:29 PM, 17th June 2011

ALBANY, US: AMRI announced it has signed a development and long term exclusive commercial supply agreement with Parnell Manufacturing Pty Ltd. Under the agreement, AMRI will provide process development, manufacturing and supply of active pharmaceutical ingredients (APIs) to support Parnell’s submission of a New Animal Drug Application (NADA) with the US Food and Drug Administration (FDA) and commercial launch of its veterinary product onto the US market pending regulatory approval. The development and manufacture of this API will take place at AMRI’s facilities in Albany, NY.

“Parnell sought expressions of interest for the development and long term supply of this API from several companies and we are pleased that AMRI was ultimately successful in their tender. This product is an extremely important project for Parnell and the FDA compliant development is paramount to the successful launch,” said Robert Joseph, CEO, Parnell.

0 Comments

Your Comments (Up to 2000 characters)

Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Submit

NEW YORK, US: SK Capital Partners announced that it has partnered with Charles Cogliandro, Chief Executive Officer to recapitalize Houston-based Cal ...

Asahi Kasei launches new mid-term management initiative

The Asahi Kasei Group has launched a new mid-term strategic management initiative, “For Tomorrow 2015,” for the five-year period from fi ...

Momentive, Zhejiang Xinan joint venture to expand capacity in China

ALBANY, US/JIANDE, CHINA: Momentive Performance Materials Inc and Zhejiang Xinan Chemical Industrial Group announced their joint venture company, Zh ...

Merck KGaA profit jumps with sales hikes